ライフサイエンスコーパス: transient ischemic attack

1 ds of periprocedural mortality and stroke or transient ischemic attack.

2 l ischemia during cardiac arrest or forms of transient ischemic attack.

3 s likely to be female or have a prior stroke/transient ischemic attack.

4 l death, myocardial infarction, or stroke or transient ischemic attack.

5 mic embolism, second only to prior stroke or transient ischemic attack.

6 ation (1995-1998) to risk of incident stroke/transient ischemic attack.

7 s one fatal intracerebral hemorrhage and one transient ischemic attack.

8 130 participants experienced incident stroke/transient ischemic attack.

9 Secondary outcome was stroke or transient ischemic attack.

10 tic peripheral vascular disease, stroke, and transient ischemic attack.

11 ,940 participants without previous stroke or transient ischemic attack.

12 arged with a diagnosis of ischemic stroke or transient ischemic attack.

13 arge proportion of strokes are preceded by a transient ischemic attack.

14 en considerable scientific inquiry regarding transient ischemic attack.

15 mong patients who have experienced stroke or transient ischemic attack.

16 mellitus, after a recent ischemic stroke or transient ischemic attack.

17 th insulin resistance and a recent stroke or transient ischemic attack.

18 y control subjects), and in 72 patients with transient ischemic attacks.

19 idelines for the management of patients with transient ischemic attacks.

20 t with rapidly resolving deficits resembling transient ischemic attacks.

21 .785; P=0.438) improved prediction of stroke/transient ischemic attacks.

22 arction (0.8% vs. 1.2%, p = 0.42), or stroke/transient ischemic attack (0.7% vs. 0.6%, p = 0.80).

23 failure, 2 nonfatal myocardial infarction, 2 transient ischemic attack, 1 cardiovascular death).

24 eath rate: 1.2%; recurrent MI: 16.8%; stroke/transient ischemic attack: 1.2%; revascularization: 5.8%

25 e range), stroke 123.8 pmol/l (93 to 160.5); transient ischemic attack 114.5 pmol/l (85.3 to 138.8);

26 1.3%, respectively; P = .003), to have had a transient ischemic attack (12.5% vs 6.1%, respectively;

27 cerebrovascular event (stroke: 63 patients; transient ischemic attack: 12 patients) during the 3-yea

28 osis-related groups 014-015 (Stroke and TIA [transient ischemic attack]), 164-167 (Appendectomy), 082

29 Patients with adjudicated stroke (7) and transient ischemic attacks (19 in 11 standard/8 alternat

30 There were 6 cases of stroke or transient ischemic attack (4 in the fibrinogen group); 4

31 hythmia, 8 nonfatal myocardial infarction, 5 transient ischemic attack, 5 heart failure, 2 nonfatal s

32 0.65-0.98; P=0.03) and with more strokes or transient ischemic attacks (55 [0.9%] versus 34 [0.5%];

33 n, 54%; diabetes mellitus, 30%; prior stroke/transient ischemic attack, 6.5%; arterial disease, 15.9%

34 00 patient-years), 46 (1.6%) had a stroke or transient ischemic attack (8.45/1000 patient-years), 19

35 She had a transient ischemic attack about 4 years ago when she was

36 There were 1075 stroke and transient ischemic attack admissions in the pretriage pe

37 ears, diabetes mellitus, and prior stroke or transient ischemic attack]), AF occurrence and duration,

38 In addition, 4 patients suffered transient ischemic attack after cardioversion.

39 s and characterize death and CVEs (stroke or transient ischemic attack) after HRDM procedures over a

40 ctomies from patients with symptoms (stroke, transient ischemic attacks, amaurosis fugax) than in asy

41 llation patients hospitalized with stroke or transient ischemic attack and are prescribed to patients

42 Outcome data on stroke/transient ischemic attack and bleeding complications dur

43 ion of a 'stroke-prone state' following both transient ischemic attack and completed stroke, suggesti

44 ere associated with increased risk of stroke/transient ischemic attack and improved risk prediction c

45 r, among patients with an ischemic stroke or transient ischemic attack and insulin resistance, those

46 ble to construct valid eQMs for processes of transient ischemic attack and minor ischemic stroke care

47 We sought to develop and validate transient ischemic attack and minor ischemic stroke elec

48 hly effective strategy; however, the risk of transient ischemic attack and stroke is approximately 0.

49 SETTING, AND PARTICIPANTS: The Follow -Up of Transient Ischemic Attack and Stroke Patients and Uneluc

50 alization for angina, myocardial infarction, transient ischemic attack and stroke, death, and cardiov

51 l of biomarkers with the incidence of stroke/transient ischemic attack and the prevalence of subclini

52 ata to evaluate care for their patients with transient ischemic attack and to complement and expand q

53 180 days of a qualifying ischemic stroke or transient ischemic attack and were followed for a maximu

54 er panel was associated with incident stroke/transient ischemic attack and with total cerebral brain

55 outcomes included thromboembolism or stroke/transient ischemic attacks and bleeding events.

56 ectrum of hypoperfusion disorders along with transient ischemic attacks and silent infarcts.

57 erapy for breast cancer have been related to transient ischemic attacks and stroke.

58 e substantially to morbidity associated with transient ischemic attacks and strokes (TIA-S).

59 r, diabetes mellitus, and previous stroke or transient ischemic attack) and CHA2DS2-VASc (congestive

60 romboembolism (stroke, systemic embolism, or transient ischemic attack) and major bleeding.

61 posite of myocardial infarction, stroke, and transient ischemic attack) and venous thromboembolism (V

62 hanged, 40,323 (23.2%) had a prior stroke or transient ischemic attack, and 112,174 (64.6%) had coron

63 of 67 subjects with ischemic stroke, 5 with transient ischemic attack, and 27 with ICH.

64 Geriatric Depression Scale >4, prior stroke/transient ischemic attack, and abnormal albumin received

65 ia or Latin America, older age, prior stroke/transient ischemic attack, and aspirin use at baseline.

66 complications, contrast nephropathy, stroke, transient ischemic attack, and combined end points (all

67 gnificant effect on the composite of stroke, transient ischemic attack, and death in adjusted but not

68 adverse cardiac and cerebrovascular events, transient ischemic attack, and definitive ischemic brain

69 Cohort participants free of clinical stroke, transient ischemic attack, and dementia formed our sampl

70 angina, coronary revascularization, stroke, transient ischemic attack, and heart failure.

71 etes, angina, myocardial infarction, stroke, transient ischemic attack, and kidney disease, patients

72 bserved incident CV event, including stroke, transient ischemic attack, and myocardial infarction (MI

73 Crude 30-day mortality, stroke or transient ischemic attack, and myocardial infarction ris

74 ssion for embolic (cerebrovascular accident, transient ischemic attack, and noncerebral arterial thro

75 fatal myocardial infarction, angina, stroke, transient ischemic attack, and peripheral artery disease

76 chemic stroke as well as unspecified stroke, transient ischemic attack, and pulmonary embolism) yield

77 e, first CeVD event (acute brain infarction, transient ischemic attack, and stroke-related death) alo

78 luding death, myocardial infarction, stroke, transient ischemic attack, and the composite outcome, de

79 ath, myocardial infarction, ischemic stroke, transient ischemic attack, and unstable angina.

80 eported; 76% were ischemic strokes (IS), 15% transient ischemic attacks, and 9% hemorrhagic strokes.

81 ascularization, (severe) recurrent ischemia, transient ischemic attacks, and arterial thrombotic even

82 eases such as myocardial infarction, stroke, transient ischemic attacks, and pulmonary embolism are m

83 ent or angina, intermittent claudication, or transient ischemic attack; and (2) all-cause mortality.

84 eterminations of cause of death after stroke/transient ischemic attack are not currently feasible.

85 Transient ischemic attacks are common and important harb

86 nfarction/stroke/(severe) recurrent ischemia/transient ischemic attack/arterial thrombotic events, to

87 d long-term risks of mortality and stroke or transient ischemic attack, as well as periprocedural myo

88 There was no mortality, stroke, or transient ischemic attack at 1 year in either group.

89 Two patients, 1 from each group, presented transient ischemic attack at 3-month follow-up.

90 (risk of venous thromboembolism, stroke, or transient ischemic attack) at 3 months, no significant d

91 There were no instances of stroke, transient ischemic attack, atrioesophageal fistulas, or

92 Patients who have suffered a stroke or transient ischemic attack attributed to stenosis (50-99%

93 d, without bevacizumab because of the recent transient ischemic attack; carboplatin was selected over

94 tion on the occurrence of incident stroke or transient ischemic attack, cardiovascular events, and nu

95 Preprocedural neurologic symptoms included transient ischemic attack, cerebrovascular accident, and

96 s, diabetes mellitus, and previous stroke or transient ischemic attack (CHADS2) and Anticoagulation a

97 llow-up; 35 patients had at least one CVA or transient ischemic attack (CVA/TIA).

98 Ipsilateral stroke or transient ischemic attack, death from ipsilateral stroke

99 predicted the risk of ipsilateral stroke or transient ischemic attack, death from stroke, or death f

100 seline included confirmed history of stroke, transient ischemic attack, diabetes mellitus, or hyperte

101 ence of comorbidities including prior stroke/transient ischemic attack, diabetes, and coronary artery

102 Older age, prior hemorrhage, prior stroke or transient ischemic attack, diabetes, lower creatinine cl

103 ia-related ED visits resulted in a stroke or transient ischemic attack diagnosis.

104 imary end point was a composite of stroke or transient ischemic attack during 2 years of follow-up, d

105 adjusted hazards of mortality and stroke or transient ischemic attack during and after the periproce

106 recommendations on the care of patients with transient ischemic attacks emphasize the importance of u

107 s or stroke alone) and tertiary (stroke plus transient ischemic attack) end points in the Prospective

108 spirin were age >/=75 years, prior stroke or transient ischemic attack, estimated glomerular filtrati

109 nd parameters performed similarly for stroke/transient ischemic attack event prediction.

110 nts with previous MI without prior stroke or transient ischemic attack for whom there is a clinical i

111 d to patients without a history of stroke or transient ischemic attack given its contraindication in

112 patients with cryptogenic ischemic stroke or transient ischemic attack has not been compared with tha

113 brillation patients with ischemic stroke and transient ischemic attack have not been well characteriz

114 ibrillation patients with ischemic stroke or transient ischemic attack hospitalized between October 2

115 .07-1.31), hypertension HR 1.37 (1.29-1.45), transient ischemic attack HR 2.74 (2.41-3.12), atrial fi

116 HR 1.61), renal impairment (HR 1.50), stroke/transient ischemic attack (HR 1.43), smoking (HR 1.41),

117 The only thromboembolic complication was transient ischemic attack in 1 patient (0.2%; 95% confid

118 strokes, or operative mortality (<30 days), transient ischemic attack in 1 patient, reoperation for

119 Clinical strokes were detected in 17%, transient ischemic attack in 2%, and in-hospital mortali

120 ine clearance <60 mL/min and prior stroke or transient ischemic attack in a model with no other covar

121 The primary outcome event was stroke or transient ischemic attack in any territory occurring bet

122 hemorrhage in 71 patients (87.6%), stroke or transient ischemic attack in five patients (6.2%), and o

123 hs, stroke occurred in 2 patients on OAC and transient ischemic attack in one without OAC in the LAAI

124 as good as warfarin for preventing stroke or transient ischemic attack in patients with atrial fibril

125 brovascular events consistent with stroke or transient ischemic attack in relation to mean radiograph

126 eparin-bridging group and one stroke and one transient ischemic attack in the continued-warfarin grou

127 ears, Diabetes mellitus, and prior Stroke or transient ischemic attack) index, Framingham score, and

128 diac arrest, to weak (hazard ratio <1.5) for transient ischemic attack, intracerebral hemorrhage, and

129 Whether late APC administration after a transient ischemic attack is neuroprotective and whether

130 han 1 year after an index ischemic stroke or transient ischemic attack is not associated with a great

131 Transient ischemic attack is now understood to indicate

132 -based guidelines for treatment of stroke or transient ischemic attack is suboptimal.

133 years with cerebrovascular events, including transient ischemic attack, ischemic and hemorrhagic stro

134 diabetes and for those with prior strokes or transient ischemic attacks, it has become evident that a

135 eurological complications (seizures, stroke, transient ischemic attack, learning difficulty, headache

136 Being Hispanic and having had a transient ischemic attack-like episode were predictors o

137 vealed recurrent transient motor and sensory transient ischemic attack-like symptoms over the precedi

138 ruit (LR, 0.12; 95% CI, 0.03-0.47) and prior transient ischemic attack (LR, 0.34; 95% CI, 0.18-0.65).

139 st that patients with a history of stroke or transient ischemic attack may constitute a population di

140 Transient ischemic attack may simply highlight the dynam

141 stinguish recrudescence from mimics, such as transient ischemic attacks, migraine, Todd paralysis, an

142 ly associated with delirium: prior stroke or transient ischemic attack, Mini Mental State Examination

143 [4.8-fold; P=7.8x10(-9)]) and patients with transient ischemic attack (miR-125a-5p: P=0.003; miR-125

144 , coronary artery bypass grafting, stroke or transient ischemic attack, myocardial infarction, and re

145 first AF, congestive heart failure, stroke, transient ischemic attack, myocardial infarction, corona

146 nd point was a composite of ischemic stroke, transient ischemic attack, myocardial infarction, or oth

147 neutropenia (n = 2), leukopenia (n = 1), and transient ischemic attack (n = 1).

148 e (n = 124; 65.6%) compared to patients with transient ischemic attack (n = 16; 8.5%) and to patients

149 ys (mRS = 1) (95% CI: 1.3%, 8.4%), including transient ischemic attack (n = 2), small cerebral infarc

150 n = 69), edema (n = 30), and previous stroke/transient ischemic attack (n = 21).

151 who reported a physician diagnosis of stroke/transient ischemic attack (n = 647) or stroke symptoms (

152 embolic events (3.7% strokes [n=29] and 1.3% transient ischemic attacks [n=10]) in group 1: two event

153 bacute stroke, n = 2; chronic stroke, n = 3; transient ischemic attack, n = 2) underwent 3D time-of-f

154 Transient ischemic attack occurred in 1 (1%) patient 2 d

155 Periprocedural stroke/transient ischemic attack occurred in 27 patients (1.1%)

156 Stroke or transient ischemic attack occurred in 66 (0.8%) randomiz

157 In the CAS group, recurrent stroke or transient ischemic attack occurred more often among DWI+

158 Cerebrovascular accidents/transient ischemic attacks occurred in 26 patients (13%)

159 ular disease-related death, ischemic stroke, transient ischemic attack) occurred in 41 subjects.

160 in patient subgroups presenting with stroke, transient ischemic attack, ocular symptoms, and asymptom

161 low: recent history (<6 months) of stroke or transient ischemic attack (odds ratio [OR] 2.8, 95% conf

162 fect was driven by a decrease in the risk of transient ischemic attack of 5% versus 14%, respectively

163 = 75, diabetes mellitus, and prior stroke or transient ischemic attack) of > or = 3.

164 rs of mortality were remote (> or =6 months) transient ischemic attack or cerebrovascular accident, s

165 ulticenter trial involving 569 patients with transient ischemic attack or ischemic stroke due to 50%

166 Two hundred consecutive deaths of transient ischemic attack or ischemic stroke patients we

167 METHODS AND A random sample of patients with transient ischemic attack or minor ischemic stroke, care

168 xyglucose PET/CT in 26 patients after recent transient ischemic attack or minor ischemic stroke: 18 p

169 acute infarct or hemorrhage, no evidence of transient ischemic attack or seizure, no acute lesion on

170 ry (51% vs 32%, P < .001), or had history of transient ischemic attack or stroke (16% vs 10%, P < .00

171 Participants with recent VB transient ischemic attack or stroke and 50% or more athe

172 randomly assigned patients who had a recent transient ischemic attack or stroke attributed to stenos

173 We randomly assigned patients with transient ischemic attack or stroke caused by angiograph

174 In group 1, transient ischemic attack or stroke was the presenting s

175 events were common: 19.2% of patients had a transient ischemic attack or stroke, 19.7% had experienc

176 e mortality, nonfatal myocardial infarction, transient ischemic attack or stroke, and heart failure r

177 rteries, either manifesting as hypertension, transient ischemic attack or stroke, respectively.

178 cular events among patients with PFO-related transient ischemic attack or stroke.

179 er age were independent predictors of stroke/transient ischemic attack or systemic embolism.

180 s [2 points], diabetes mellitus, and stroke, transient ischemic attack or thromboembolism [2 points]-

181 ubled], type 1 or type 2 diabetes, stroke or transient ischemic attack or thromboembolism [doubled],

182 75 years, Diabetes mellitus, prior Stroke or transient ischemic attack or thromboembolism, Vascular d

183 nd subsequent vascular complications such as transient ischemic attacks or stroke.

184 (OR, 2.523), and the comorbidity of frequent transient ischemic attack (OR, 1.674).

185 ptomatic if symptoms consistent with stroke, transient ischemic attack, or amaurosis fugax had occurr

186 re asymptomatic (i.e., had not had a stroke, transient ischemic attack, or amaurosis fugax in the 180

187 eart failure, myocardial infarction, stroke, transient ischemic attack, or death) was explained by ba

188 The primary composite outcome was stroke, transient ischemic attack, or death; the secondary outco

189 Cohort participants free of clinical stroke, transient ischemic attack, or dementia (age, 61+/-9 year

190 on, heart failure, or a composite of stroke, transient ischemic attack, or other thromboembolism.

191 e primary outcome was a composite of stroke, transient ischemic attack, or peripheral embolism.

192 nd point was a composite of ischemic stroke, transient ischemic attack, or peripheral embolism.

193 cluding 18% of those with a previous stroke, transient ischemic attack, or systemic embolic event.

194 TE was defined as stroke, transient ischemic attack, or systemic embolism.

195 ed 4.7+/-0.8 cm; and 48% had a prior stroke, transient ischemic attack, or systemic embolism.

196 manent AF (p < 0.001) and history of stroke, transient ischemic attack, or systemic embolus (p = 0.01

197 = 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism [doubled])

198 n, age, diabetes mellitus, and prior stroke, transient ischemic attack, or thromboembolism) score >/=

199 5 years; Diabetes mellitus; previous Stroke, transient ischemic attack, or thromboembolism; Vascular

200 cessful closure (15%) had evidence of stroke/transient ischemic attack (p = 0.61).

201 After an ischemic stroke or transient ischemic attack, patients at higher risk for s

202 dial infarction [MI], heart failure, stroke, transient ischemic attack, peripheral arterial complicat

203 h stroke scale score >0, prior stroke, prior transient ischemic attack, peripheral vascular disease,

204 d up from procedure date until death, stroke/transient ischemic attack, periprocedural myocardial inf

205 Patients with ischemic stroke or transient ischemic attack presumably related to patent f

206 le sex, higher body mass index, prior stroke/transient ischemic attack, prior systemic embolism, and

207 cardiovascular death and increased stroke or transient ischemic attack provide a rationale for future

208 ith ischemic stroke have recurrent stroke or transient ischemic attack, rather than myocardial infarc

209 rtality, congestive heart failure, stroke or transient ischemic attack, recurrent acute rheumatic fev

210 dial infarction, cerebrovascular accident or transient ischemic attack, renal insufficiency or failur

211 in 47 (7.3%) and 2 (0.3%) patients (both had transient ischemic attacks) respectively.

212 nsion, age>75, diabetes, and prior stroke or transient ischemic attack) risk (70.9% to 59.5% for CHAD

213 ears, diabetes mellitus, and prior stroke or transient ischemic attack) score >/=1, who were consider

214 ears, diabetes mellitus, and previous stroke/transient ischemic attack) score >/=2 or 1 and another r

215 ears, diabetes mellitus, and prior stroke or transient ischemic attack) score >2, no stroke/transient

216 75 years, diabetes mellitus, prior stroke or transient ischemic attack) score than men (1.99 [SD, 1.1

217 >75, Diabetes mellitus, and prior stroke or transient ischemic attack] score >/=2).

218 75 years, Diabetes mellitus, previous Stroke/transient ischemic attack) scores of 0 to 1, representin

219 ptide], and clinical history of prior stroke/transient ischemic attack)-stroke risk score and compare

220 The 30-day transient ischemic attack, stroke, and death rates were

221 The 30-day transient ischemic attack, stroke, and death rates were

222 ed emergency hospitalization for arrhythmia, transient ischemic attack, stroke, myocardial infarction

223 ents with recent symptomatic carotid events (transient ischemic attack, stroke, or amaurosis fugax),

224 ents with recent symptomatic carotid events (transient ischemic attack, stroke, or amaurosis fugax),

225 ation applies to adults without a history of transient ischemic attack, stroke, or other neurologic s

226 le range [IQR]: 0.22 to 1.15; p = 0.008) and transient ischemic attack/stroke (median difference: 0.1

227 primary endpoint was the 30-day incidence of transient ischemic attack/stroke or new ischemic lesions

228 e clopidogrel also significantly reduced the transient ischemic attack/stroke rate at 30 days (0% vs.

229 There was a similar number of stroke/transient ischemic attack/systemic embolic events (6 ver

230 ated in patients with a history of stroke or transient ischemic attack, the analysis (n=16 896) exclu

231 f death, nonfatal coronary ischemia, stroke, transient ischemic attack, thromboembolism, or heart fai

232 age >/=75 years [doubled], diabetes, stroke/transient ischemic attack/thromboembolism [doubled], vas

233 Prior studies of stroke and transient ischemic attack (TIA) after transcatheter aort

234 We compared rates of stroke or transient ischemic attack (TIA) among patients using rhy

235 e who presented with a cryptogenic stroke or transient ischemic attack (TIA) and had a patent foramen

236 Rates of stroke/transient ischemic attack (TIA) and heart failure hospit

237 sclerotic plaque rupture is thought to cause transient ischemic attack (TIA) and ischemic stroke (IS)

238 Patients with transient ischemic attack (TIA) are at increased risk fo

239 Patients with ischemic stroke or transient ischemic attack (TIA) are at increased risk fo

240 tery disease have identified previous stroke/transient ischemic attack (TIA) as a marker of increased

241 sterol values and who had no prior stroke or transient ischemic attack (TIA) at baseline.

242 Transient ischemic attack (TIA) can be difficult to diag

243 redictors of periprocedural stroke or stroke/transient ischemic attack (TIA) combined.

244 coronary syndromes and history of stroke or transient ischemic attack (TIA) have an increased rate o

245 e whether a PFO increases the risk of stroke/transient ischemic attack (TIA) in patients with endocar

246 currence after an initial ischemic stroke or transient ischemic attack (TIA) may be impacted by undia

247 s >/=55 years without a history of stroke or transient ischemic attack (TIA) of the Rotterdam Study,

248 12 to 20% during the first 3 months after a transient ischemic attack (TIA) or minor stroke.

249 ound (TCD), are markers of future stroke and transient ischemic attack (TIA) risk.

250 eedom from cerebrovascular accident (CVA) or transient ischemic attack (TIA), and 30-day mortality.

251 ocardial infarction or CHD death), stroke or transient ischemic attack (TIA), congestive heart failur

252 prospective cohort study of prognosis after transient ischemic attack (TIA), ischemic stroke, or hem

253 d 724 consecutive patients with a first-ever transient ischemic attack (TIA), ischemic stroke, or int

254 CCE, which included a composite of stroke or transient ischemic attack (TIA), myocardial infarction,

255 a patent foramen ovale and ischemic stroke, transient ischemic attack (TIA), or a peripheral thrombo

256 idered a minor ischemic stroke, a subtype of transient ischemic attack (TIA), or a separate ischemic

257 without associated increased risk of stroke, transient ischemic attack (TIA), or death.

258 6.5 days; interquartile range, 4-8) stroke, transient ischemic attack (TIA), or retinal embolism and

259 cumented clinical chickenpox and a stroke or transient ischemic attack (TIA).

260 ute ischemic lesions and might help diagnose transient ischemic attack (TIA).

261 ine care of patients with ischemic stroke or transient ischemic attack (TIA).

262 scular outcomes in acute ischemic stroke and transient ischemic attack (TIA).

263 te the morphology with the history of stroke/transient ischemic attack (TIA).

264 Symptom duration less than 24 h defines transient ischemic attack (TIA).

265 h vascular events in patients with stroke or transient ischemic attack (TIA).

266 ance in patients with a history of stroke or transient ischemic attack (TIA).

267 ardiographic abnormalities, and incidence of transient ischemic attack (TIA)/stroke and myocardial is

268 75 years, Diabetes mellitus, previous Stroke/transient ischemic attack [TIA], Vascular disease, Age 6

269 or strokes (1.1%), 2 minor strokes (1.1%), 3 transient ischemic attacks (TIAs) (1.7%), and 1 major ac

270 Daily counts of ischemic strokes/transient ischemic attacks (TIAs) (2001-2005) were obtai

271 Transient ischemic attacks (TIAs) are common and portend

272 ned very brief focal ischemia that simulates transient ischemic attacks (TIAs) that occur in humans.

273 and clinical outcomes (including strokes and transient ischemic attacks [TIAs]).

274 en had a clinical recurrence (29 strokes, 46 transient ischemic attacks [TIAs], 4 deaths with reinfar

275 0 years or older with a history of stroke or transient ischemic attack to achieve a target systolic b

276 ants without clinical histories of stroke or transient ischemic attack underwent brain MRI in 1992 an

277 the mechanisms of this instability following transient ischemic attack using imaging studies have led

278 oration and tamponade, pneumothorax, stroke, transient ischemic attack, vascular access complications

279 rterial thromboembolic events, MI, stroke or transient ischemic attack, vascular deaths, and major va

280 older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, 65 to 74 ye

281 older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, 65 to 74 ye

282 older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65 to 7

283 ge >/=75, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, age 65 to 7

284 age >/= 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 7

285 older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, age 65 to 7

286 , age >/=75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 7

287 ge >/=75, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, age 65 to 7

288 , age >/=75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65-74 y

289 ension, age >/=75, diabetes, prior stroke or transient ischemic attack, vascular disease, age 65-74,

290 or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, aged 65 to

291 rtension, diabetes mellitus, previous stroke/transient ischemic attack, vascular diseases, chronic ki

292 h a history of stroke, systemic embolism, or transient ischemic attack was 39.4%/y versus 30.3%/y wit

293 ansient ischemic attack) score >2, no stroke/transient ischemic attack was reported in group 3.

294 Risk for stroke or transient ischemic attack was similar to the expected po

295 y heart disease (CHD) events, and 196 stroke/transient ischemic attacks were observed.

296 on, heart failure, diabetes, or prior stroke/transient ischemic attack) were randomized to either the

297 She initially presented after a transient ischemic attack, when a chest radiograph demon

298 30-day strokes (minor and major strokes and transient ischemic attacks) with TAVR (5.5% vs. 2.4%, p

299 icipants had a qualifying ischemic stroke or transient ischemic attack within 180 days of entry and i

300 and the primary safety outcome was stroke or transient ischemic attack within 30 days.